Abstract
The prolactin (PRL) permeation through the pericardium depending on the species of origin (porcine, bovine and ovine) was studied, and the parameters of its bioavailability were calculated. An in vitro model using pericardium as a natural membrane and Frantz cell method was applied.
Significant differences in permeation were observed depending on the species of origin. Within 5 h, 17.5% of bovine PRL, 27.2% of porcine PRL and 90.3% of ovine PRL permeated the pericardium. The amount of permeated ovine PRL was 3.3-fold higher than porcine PRL and 5.2-fold higher than bovine PRL. The maximum concentration of permeated PRL was reached in the thirtieth minute of the experiment and was the highest for ovine PRL (Cmax = 677.21 μg/cm2) and the lowest for bovine PRL (Cmax=259.97 μg/cm2). Bioavailability of PRL through the pericardium is 3.3-fold greater for ovine PRL in comparison to porcine or bovine PRL. The relative extent of bioavailability for bovine and ovine prolactin versus the porcine PRL standard was 85.6% and 229.3%, respectively.
Keywords: bioavailability, pericardium, permeation, PRL, prolactinbioavailability, pericardium, permeation, PRL, prolactin
Protein & Peptide Letters
Title: Study of Prolactin Permeation Through the Pericardium and Its Bioavailability
Volume: 18 Issue: 6
Author(s): Barbara Dolinska, Artur Caban, Lucyna Leszczynska, Grzegorz Oczkowicz and Florian Ryszka
Affiliation:
Keywords: bioavailability, pericardium, permeation, PRL, prolactinbioavailability, pericardium, permeation, PRL, prolactin
Abstract: The prolactin (PRL) permeation through the pericardium depending on the species of origin (porcine, bovine and ovine) was studied, and the parameters of its bioavailability were calculated. An in vitro model using pericardium as a natural membrane and Frantz cell method was applied.
Significant differences in permeation were observed depending on the species of origin. Within 5 h, 17.5% of bovine PRL, 27.2% of porcine PRL and 90.3% of ovine PRL permeated the pericardium. The amount of permeated ovine PRL was 3.3-fold higher than porcine PRL and 5.2-fold higher than bovine PRL. The maximum concentration of permeated PRL was reached in the thirtieth minute of the experiment and was the highest for ovine PRL (Cmax = 677.21 μg/cm2) and the lowest for bovine PRL (Cmax=259.97 μg/cm2). Bioavailability of PRL through the pericardium is 3.3-fold greater for ovine PRL in comparison to porcine or bovine PRL. The relative extent of bioavailability for bovine and ovine prolactin versus the porcine PRL standard was 85.6% and 229.3%, respectively.
Export Options
About this article
Cite this article as:
Dolinska Barbara, Caban Artur, Leszczynska Lucyna, Oczkowicz Grzegorz and Ryszka Florian, Study of Prolactin Permeation Through the Pericardium and Its Bioavailability, Protein & Peptide Letters 2011; 18 (6) . https://dx.doi.org/10.2174/092986611795222704
DOI https://dx.doi.org/10.2174/092986611795222704 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?
Current Stem Cell Research & Therapy Antiviral Drug Discovery Targeting to Viral Proteases
Current Pharmaceutical Design Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews Methods to Evaluate the Inhibition of TTR Fibrillogenesis Induced by Small Ligands
Current Medicinal Chemistry Chagas Disease: Progress and New Perspectives
Current Medicinal Chemistry Takotsubo-Like Left Ventricular Dysfunction in an HIV-Infected Patient
Current HIV Research Role of Stromal-Derived Factor-1 in Mesenchymal Stem Cell Paracrinemediated Tissue Repair
Current Stem Cell Research & Therapy Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design The Anti-Oxidant Properties of Isothiocyanates: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Genomic and Non-genomic Effects of Aldosterone
Current Signal Transduction Therapy Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Current Drug Targets Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy The STAT3 Inhibitor Stattic Impairs Cardiomyocyte Mitochondrial Function Through Increased Reactive Oxygen Species Formation
Current Pharmaceutical Design Surgical Ventricular Restoration: An Operation to Reverse Remodeling - Clinical Application (Part II) (Supplementry Table)
Current Cardiology Reviews Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Current Diabetes Reviews Matrix Metalloproteinases as Valid Clinical Target
Current Pharmaceutical Design Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?
Recent Patents on Cardiovascular Drug Discovery Fabry Disease Cardiomyopathy: from Genes to Clinical Manifestations
Current Pharmaceutical Biotechnology Fitness or Fatness: The Debate Continues for AMP-Activated Protein Kinase in Heart Function
Current Cardiology Reviews